Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3

被引：0
|
作者：
Papp, K. [1 ]
Leonardi, C. [2 ]
Blauvelt, A. [3 ]
Korman, N. [4 ]
Ohtsuki, M. [5 ]
Reich, K. [6 ,7 ]
Mallbris, L. [8 ]
Ball, S. [8 ]
Erickson, J. [8 ]
Griffiths, C. E. [9 ]
机构：
[1] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] Dermatol Hamburg, Hamburg, Germany
[7] Georg August Univ, Hamburg, Germany
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2016年 / 136卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
058
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [31] Time course of ixekizumab drug levels and the relationship at week 60 to efficacy in patients with moderate-to-severe plaque psoriasis (UNCOVER-3)
    Reich, K.
    Choi, S. L.
    Jackson, K.
    Mallbris, L.
    Blauvelt, A.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 39 - 39
  • [32] Ixekizumab treatment improves skin-related sexual difficulties in patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2 and-3)
    Guenther, L. C.
    Foley, P.
    Cather, J.
    Bleakman, A. Potts
    Burge, R.
    Zhu, B.
    van de Kerkhof, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 79 - 80
  • [33] Efficacy and safety of ixekizumab for the treatment of plaque psoriasis: Results through 108 weeks randomised, phase III clinical trial (UNCOVER-3)
    Blauvelt, A.
    Gooderham, M.
    Iversen, L.
    Ball, S.
    Zhang, L.
    Agada, N.
    Reich, K.
    Dossenbach, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
  • [34] Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study (UNCOVER-1)
    Gordon, Kenneth
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel K.
    Erickson, Janelle
    Zhao, Fangyi
    Shrom, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Leonardi, Craig
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
  • [35] Long-term efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis sustained for three years: Results of a randomized controlled phase 3 study (UNCOVER-3)
    Leonardi, Cathy L.
    Maari, Catherine
    Philipp, Sandra
    Crowley, Jeffrey
    Zhang, Lu
    Ball, Susan
    Mallbris, Lotus
    Gonzalez, Pablo
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB180 - AB180
  • [36] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
    Andrew Blauvelt
    Kim A. Papp
    Christopher E. M. Griffiths
    Luis Puig
    Jamie Weisman
    Yves Dutronc
    Lisa Farmer Kerr
    Dapo Ilo
    Lotus Mallbris
    Matthias Augustin
    American Journal of Clinical Dermatology, 2017, 18 : 273 - 280
  • [37] Efficacy of ixekizumab in patients with and without previous experience with biologic therapies compared to etanercept and placebo: results from UNCOVER-2, a phase 3 trial in patients with plaque psoriasis
    Lacour, Jean-Philippe
    Dutronc, Yves
    Zhang, Lu
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S6 - S6
  • [38] Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study
    Lebwohl, M. G.
    Gordon, K. B.
    Gallo, G.
    Zhang, L.
    Paul, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (02) : 301 - 309
  • [39] Efficacy of Ixekizumab in Patients with and without Previous Experience with Biologic Therapies Compared to Etanercept and Placebo: Results from UNCOVER-2, a Phase 3 Trial in Patients with Plaque Psoriasis
    Lacour, J. -P.
    Leutz, A.
    Dutronc, Y.
    Zhang, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [40] Ixekizumab treatment shows a neutral impact on the glucose and lipid profile of patients with moderate-to-severe psoriasis: Results from UNCOVER-1,-2, and-3
    Wu, J. J.
    Egeberg, A.
    Solomon, J. A.
    Osuntokun, O.
    Goldblum, O.
    Moriarty, S.
    Zhao, F.
    Korman, N.
    Vincent, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S260 - S260
12345